Treatment with poly(ADP-ribose) polymerase inhibitors (PARPis) has been evaluated for nearly 10 years in recurrent ovarian cancer—first in patients with a BRCA1/2 mutation and later in patients without a BRCA1/2 mutation [6,7,8,9]. This evidence concerns the gene BRCA1 and ovarian cancer.